Tardive Dyskinesia (TD) is a late-onset, drug-induced hyperkinetic movement disorder after chronic dopamine D₂ blockade. It classically presents with involuntary orofacial and limb/trunk movements that persist beyond 4–8 weeks and may be irreversible. Risk remains with atypicals (risperidone/olanzapine), especially at higher doses, older age, female sex, and longer exposure.

🔎 Definitions & Timing

Latency: usually months–years after exposure; can appear after dose reduction or cessation (“withdrawal-emergent”).
Persistence: symptoms last ≥1 month after stopping the drug (typical teaching ≥3 months).
Core phenotype: choreo-athetoid movements (face, tongue, jaw) ± limbs/trunk; suppressible briefly; worsen with stress.

🧠 Pathophysiology (teaching pearl)

D₂ supersensitivity: chronic blockade → up-regulation on striatal medium spiny neurons → hypersynchronous outputs.
Maladaptive plasticity & oxidative stress: altered corticostriatal synaptic scaling; cumulative neurotoxic stress in basal ganglia.
Genetic vulnerability (drug metabolism/receptor variants) likely explains inter-individual risk differences.

⚠️ Risk Factors

Advanced age; female sex; mood disorders; diabetes; cumulative dose/duration; prior EPS; anticholinergic co-prescription; learning disability or brain injury.
High-risk drugs: typical antipsychotics (haloperidol, fluphenazine) > risperidone/olanzapine > quetiapine/clozapine (lowest).
Non-psychiatric culprit: metoclopramide (MHRA: restrict to short courses, usually ≤5 days).

🧩 Clinical Features

Oro-bucco-lingual: grimacing, lip smacking, tongue protrusion/rolling, chewing; blepharospasm.
Limbs/trunk: chorea/athetosis, piano-playing fingers, pelvic thrusting, rocking; respiratory dyskinesia (rare).
Functional impact: speech/swallowing difficulty, social stigma, dental trauma, pain, falls.

🆚 Differentiate from Other Drug-Induced Movement Disorders

Syndrome	⏱ Timing	🤸 Phenotype	🔍 Key Clues	💊 Management
Tardive dyskinesia	📆 Months–years (± withdrawal-emergent)	Choreo-athetoid orofacial + limb movements	Persist >4–8 wks Exacerbated by stress	🔄 Optimise/↓ antipsychotic 🧪 VMAT2 inhibitor (valbenazine, deutetrabenazine) 🚫 Avoid anticholinergics
Akathisia	📅 Days–weeks	Inner restlessness Constant pacing, shifting	Subjective “can’t sit still” misery Movements non-choreiform	↘ Reduce dose 💊 Propranolol or mirtazapine 🧘 Clonazepam option
Acute dystonia	⏳ Hours–days	Sustained spasms (oculogyric crisis, torticollis, trismus)	Young ♂ more affected Linked to high-potency D₂ blockers	💉 IM/IV procyclidine or benztropine ⏱ Usually short-term cover

The content on this website is provided for educational and informational purposes only to support exam preparation (e.g., MLA, MRCP, USMLE) and learning. This is NOT medical advice, diagnosis, treatment, or professional guidance. It does not replace consultation with a qualified healthcare professional, official guidelines (e.g., NICE, GMC, BNF), or supervised clinical practice. Always verify information with current, authoritative sources. Makindo and its contributors accept no liability for any reliance on this content, including errors, omissions, or any resulting harm, loss, or consequences. By using this site, you agree to these terms.

Tardive Dyskinesias

🔎 Definitions & Timing

🧠 Pathophysiology (teaching pearl)

⚠️ Risk Factors

🧩 Clinical Features

🆚 Differentiate from Other Drug-Induced Movement Disorders

Categories